|
Delayed
Berne S.E.
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
| Market Cap | 5.32B 4.72B 4.42B 4B 7.56B 512B 7.61B 53.04B 20.63B 261B 19.96B 19.53B 840B | P/E 2026 * |
41.3x | P/E 2027 * | 24.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3.45B 3.06B 2.86B 2.59B 4.9B 332B 4.93B 34.38B 13.37B 169B 12.93B 12.66B 545B | EV / Sales 2026 * |
2.74x | EV / Sales 2027 * | 2.3x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PTC Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 54 | 2023-03-21 |
Pierre Gravier
DFI | Director of Finance/CFO | 41 | 2023-07-12 |
| Chief Tech/Sci/R&D Officer | - | 2017-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 2004-10-31 | |
Allan Jacobson
CHM | Chairman | 80 | 1998-03-30 |
David Southwell
BRD | Director/Board Member | 65 | 2005-11-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 5.32B | |
| +1.26% | -2.29% | +36.97% | +104.79% | 1,032B | |
| +0.73% | -4.78% | +35.41% | +61.62% | 614B | |
| +0.35% | +1.29% | +15.86% | +79.90% | 471B | |
| +1.72% | -4.92% | +59.84% | +36.64% | 350B | |
| +1.29% | +1.66% | +23.02% | +41.48% | 337B | |
| +1.19% | -1.02% | +12.91% | +34.73% | 268B | |
| +0.10% | -2.18% | -6.01% | +10.65% | 246B | |
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | |
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | |
| Average | +0.35% | -3.39% | +26.87% | +57.03% | 412.76B | |
| Weighted average by Cap. | +0.09% | -3.18% | +29.85% | +67.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.26B 1.12B 1.04B 947M 1.79B 121B 1.8B 12.55B 4.88B 61.85B 4.72B 4.62B 199B | 1.38B 1.22B 1.14B 1.04B 1.96B 133B 1.97B 13.74B 5.34B 67.71B 5.17B 5.06B 218B |
| Net income | 145M 129M 121M 109M 207M 14.02B 208M 1.45B 564M 7.15B 546M 534M 22.99B | 218M 194M 181M 164M 311M 21.05B 313M 2.18B 847M 10.74B 820M 802M 34.52B |
| Net Debt | -1.87B -1.66B -1.55B -1.41B -2.66B -180B -2.68B -18.67B -7.26B -92.02B -7.02B -6.87B -296B | -2.15B -1.9B -1.78B -1.62B -3.05B -207B -3.07B -21.41B -8.33B -106B -8.05B -7.88B -339B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTCT Stock
- P91 Stock
Select your edition
All financial news and data tailored to specific country editions
